Detailed explanation of side effects, prevention and treatment methods of Almonertinib

Almonertinib is a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) independently developed in China. It is mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR mutations. It is especially effective in patients with T790M drug-resistant mutations. As a targeted drug, ametinib has obvious advantages in improving tumor progression and prolonging progression-free survival. However, like all targeted drugs, it may also produce certain side effects. Understanding the manifestations, prevention and treatment methods of these side effects is of great significance for maximizing clinical drug safety and efficacy.

Common side effects of ametinib mainly include rash, diarrhea, stomatitis, fatigue, decreased appetite, and abnormal liver function. Rash usually manifests as erythema and papules on the face, neck or upper limbs, and in severe cases may be accompanied by itching or scaling; diarrhea is usually mild to moderate, and occasionally causes dehydration or electrolyte imbalance; stomatitis manifests as oral mucosal pain, ulcers or inflammation; fatigue and loss of appetite may affect the patient's quality of life. In addition, some patients may experience increased liver function indicators (such as increased ALT and AST), and a few patients may experience decreased platelet or white blood cell counts. Although serious adverse events are rare, close monitoring is required.

In terms of preventing side effects, patients should undergo a comprehensive physical examination before taking the drug, including liver and kidney function, blood routine, and evaluation of past diseases. Patients with a high risk of rash can use measures such as gentle skin care, avoiding strong light exposure, and keeping the skin clean and moist to prevent rash; for patients who are prone to diarrhea, they should pay attention to a light diet, eat less high-fat or irritating foods, and maintain adequate fluid intake. Regular monitoring of liver function indicators and hematological indicators can help detect potential problems early and intervene in a timely manner.
When side effects occur, corresponding measures should be taken according to the degree. For mild to moderate rashes, topical moisturizers and topical glucocorticoid ointments can be used. For severe rashes, medication needs to be suspended or reduced under the guidance of a doctor. Diarrhea can be controlled through rehydration, electrolyte balance, and anti-diarrheal drugs, and the drug dosage can be adjusted if necessary. Oral care solutions, topical analgesics, or oral moisturizers can be used for stomatitis. Abnormal liver function requires close monitoring of indicators, suspension of medication if necessary, and adjustment of dosage according to the situation. In general, most of the side effects of ametinib are controllable. Through early prevention, regular monitoring and timely treatment, patients can use the drug safely and long-term to fully exert its anti-tumor efficacy.
In clinical practice, medical staff should develop personalized medication and follow-up plans based on individual patient differences, and educate patients to pay attention to side effects and report them in a timely manner. Combined with standardized management and active intervention strategies, ametinib can not only provide targeted efficacy in the treatment of non-small cell lung cancer, but also minimize the impact of side effects on patients' quality of life, thereby achieving a balance between treatment safety and effectiveness.
Reference link: https://www.drugs.com